N
130.71
0.00 (0.00%)
| Penutupan Terdahulu | 130.71 |
| Buka | 130.43 |
| Jumlah Dagangan | 734,670 |
| Purata Dagangan (3B) | 1,119,942 |
| Modal Pasaran | 13,118,509,056 |
| Harga / Pendapatan (P/E TTM) | 27.99 |
| Harga / Pendapatan (P/E Ke hadapan) | 21.19 |
| Harga / Jualan (P/S) | 4.68 |
| Harga / Buku (P/B) | 4.03 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 4 May 2026 |
| Margin Keuntungan | 12.68% |
| Margin Operasi (TTM) | 4.14% |
| EPS Cair (TTM) | 2.95 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 11.10% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | -81.80% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 19.45% |
| Nisbah Semasa (MRQ) | 3.13 |
| Aliran Tunai Operasi (OCF TTM) | 529.90 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 235.48 M |
| Pulangan Atas Aset (ROA TTM) | 8.75% |
| Pulangan Atas Ekuiti (ROE TTM) | 12.43% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Drug Manufacturers - Specialty & Generic (US) | Bercampur | Bercampur |
| Drug Manufacturers - Specialty & Generic (Global) | Bercampur | Bercampur | |
| Stok | Neurocrine Biosciences, Inc. | Menurun | Menaik |
AISkor Stockmoo
0.2
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | -1.5 |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | -1.0 |
| Osilator Teknikal | -0.5 |
| Purata | 0.20 |
|
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. |
|
| Sektor | Healthcare |
| Industri | Drug Manufacturers - Specialty & Generic |
| Gaya Pelaburan | Mid Core |
| % Dimiliki oleh Orang Dalam | 1.06% |
| % Dimiliki oleh Institusi | 98.86% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Dodge & Cox | 31 Dec 2025 | 5,508,042 |
| Bnp Paribas Asset Management Holding S.A. | 31 Dec 2025 | 1,395,902 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 204.00 (Citigroup, 56.07%) | Beli |
| Median | 175.50 (34.27%) | |
| Rendah | 140.00 (BMO Capital, 7.11%) | Pegang |
| 140.00 (Truist Securities, 7.11%) | Beli | |
| Purata | 171.08 (30.89%) | |
| Jumlah | 10 Beli, 2 Pegang | |
| Harga Purata @ Panggilan | 126.75 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Wolfe Research | 24 Feb 2026 | 160.00 (22.41%) | Beli | 130.96 |
| JP Morgan | 17 Feb 2026 | 176.00 (34.65%) | Beli | 127.76 |
| 12 Jan 2026 | 177.00 (35.41%) | Beli | 132.66 | |
| Truist Securities | 17 Feb 2026 | 140.00 (7.11%) | Beli | 127.76 |
| 08 Jan 2026 | 169.00 (29.29%) | Beli | 135.57 | |
| Wells Fargo | 13 Feb 2026 | 175.00 (33.88%) | Beli | 124.12 |
| BMO Capital | 12 Feb 2026 | 140.00 (7.11%) | Pegang | 123.10 |
| Citigroup | 12 Feb 2026 | 204.00 (56.07%) | Beli | 123.10 |
| HC Wainwright & Co. | 12 Feb 2026 | 192.00 (46.89%) | Beli | 123.10 |
| Needham | 12 Feb 2026 | 185.00 (41.53%) | Beli | 123.10 |
| RBC Capital | 12 Feb 2026 | 177.00 (35.41%) | Beli | 123.10 |
| Wedbush | 12 Feb 2026 | 151.00 (15.52%) | Beli | 123.10 |
| UBS | 23 Jan 2026 | 178.00 (36.18%) | Beli | 136.18 |
| Morgan Stanley | 08 Jan 2026 | 175.00 (33.88%) | Pegang | 135.57 |
| Papar semua | ||||
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 26 Jan 2026 | Pengumuman | Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1065890 in Adults with Tardive Dyskinesia |
| 21 Jan 2026 | Pengumuman | Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2025 Financial Results |
| 15 Jan 2026 | Pengumuman | Neurocrine Biosciences Presents Head-to-Head INGREZZA® (valbenazine) Capsules Data Demonstrating Higher VMAT2 Target Occupancy Compared to AUSTEDO XR |
| 05 Jan 2026 | Pengumuman | Neurocrine Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference |
| 22 Dec 2025 | Pengumuman | Neurocrine Biosciences Provides Update on Phase 3 Study of Valbenazine in Dyskinetic Cerebral Palsy |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |